

Press Release

Neurogastrx to Present Novel Gastroparesis Drug Candidate in Podium Presentation at Digestive Disease Week 2016

Lecture to highlight potent dopamine receptor antagonist with limited propensity to cross blood brain barrier

Campbell, CA – May 23, 2016 – Neurogastrx, a biopharmaceutical company engaged in developing novel drugs for gastrointestinal disorders, today announced the Company will present data from its lead gastrointestinal research program during Digestive Disease Week (DDW) 2016 in San Diego, May 21 through May 24, 2016. Cyril De Colle, Ph.D., Neurogastrx' Chief Scientific Officer will deliver the oral presentation detailing data from nonclinical studies of the Company's lead drug candidate, NG101, a potent and selective dopamine receptor antagonist, the only class of drugs approved for gastroparesis.

The abstract to be presented follows and may be viewed in full [here](#).

Tuesday, May 24, 2:00-3:30pm:

AGA Session: *Gastroparesis: Bench to Bedside*

Oral Session #1079: "NG101: A Potent and Selective Dopamine D2 Receptor Antagonist as a Potential Alternative to Metoclopramide and Domperidone for the Treatment of Gastroparesis"

"Existing dopamine receptor antagonists and various formulations of these agents are not satisfactory therapeutic interventions due to neurological or cardiovascular side effects. Neurological side effects occur primarily due to these agents crossing the blood brain barrier (BBB) and interfering with dopamine receptors in the central nervous system. Our data show NG101 does not readily cross the BBB; therefore, we believe NG101 will prove to be a safer alternative to these agents and offer physicians a welcome therapeutic alternative for the treatment of gastroparesis", stated Dr. De Colle.

###

About Gastroparesis

Gastroparesis is a syndrome characterized by delayed gastric emptying in the absence of mechanical obstruction of the stomach. The specific cause of gastroparesis is unknown, however, many cases are symptoms of other diseases such as diabetes mellitus, Parkinson's disease, multiple sclerosis, or scleroderma. Population-based studies have shown that approximately 20% of patients with diabetes and all patients with Parkinson's disease have upper GI symptoms. Only one product, metoclopramide, a potent dopamine D2 receptor antagonist, is currently approved for the treatment of gastroparesis in the US. However, metoclopramide has an FDA-imposed black box warning and limited treatment duration due to

significant risk of tardive dyskinesia (or drug-induced Parkinsonism), due to its impact on the central nervous system.

About NG 101

NG101 is a potent, selective and peripherally-restricted dopamine D2 receptor antagonist that has been safely used in Europe for decades for the treatment of acute conditions. Unlike many dopamine receptor antagonists, NG101 does not readily cross the blood-brain barrier at therapeutic concentrations.

About Neurogastrx

Neurogastrx is a private biopharmaceutical company focused on discovering and developing transformative therapies for gastrointestinal disorders affecting the enteric nervous system. For more information, please visit www.neurogastrx.com.

Investors and Media:

Baxter Phillips III
+1.804.754.5442
baxter.phillips@neurogastrx.com